Savient begins Krysexxa shipment soon; ThermoGenesis inks distribution agreement;

 @FierceBiotech: CRO Charles River ($CRL) cuts 300 more jobs. Report | Follow @FierceBiotech

> Savient will begin shipping its gout drug, Krystexxa, on Nov. 30, 2010, with sales beginning Dec. 1. The company did not disclose the drug's price; it also released its third quarter financial results, which included a net loss of $59.4 million. Savient release

> Researchers may have found an early source of Parkinson's Disease: an energy crisis in the brain. Story

> ThermoGenesis has signed a distribution agreement covering China and Hong Kong for its products used to prepare cell concentrates, including stem cells, from bone marrow, at the point-of-care and in the laboratory. Report

> Nanoshells--hollow silica spheres covered with gold--were invented and are being tested in Houston. And they continue to surprise researchers with how effective they are. Researchers say they are killing breast cancer cells at a previously unreachable root level. Report

> Rules-Based Medicine has reached a major milestone with the commercial release of VeriPsych, a diagnostic test that looks at a complex array of 51 biomarkers to help physicians come up with a diagnosis of early-stage schizophrenia. But the test, the first blood-based tool of its type, has triggered a sharp debate among the experts about its accuracy and usefulness. Story

> The FDA is teaming up with drug developers, academics and others on a new program that urges regulators to agree on disease-specific biomarkers that can be used in the clinical trial process. And their goal is to find out earlier if they're on the right track or need to move on--cutting costs and shortening development cycles. Report

And Finally... The 26 vaccine-preventable diseases. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.